Omar Abdel-Wahab is an Assistant Member in the Human Oncology and Pathogenesis Program (HOPP) and an Attending Physician on the Leukemia Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center. Dr. Abdel-Wahab’s research focuses on the role of disordered epigenetic modifiers in the pathogenesis of hematopoietic malignancies.
Omar I. Abdel-Wahab, MD
Associate Professor
Research Focus
Physician-scientist Omar Abdel-Wahab studies the functional genomics of hematopoietic malignancies.Education
MD, Duke University School of MedicineLab Members
Young Rock Chung
Research Technician
Benjamin Durham
Research Fellow
Monisha Hosier
Administrative Assistant II
Daichi Inoue
Research Fellow
Stanley Lee
Research Fellow
Bo Liu
Research Fellow
Justin Taylor
Fellow
Akihide Yoshimi
Research Fellow
Publications
- Micol JB, Pastore A, Inoue D, Duployez N, Kim E, Lee SC, Durham BH, Chung YR, Cho H, Zhang XJ, Yoshimi A, Krivtsov A, Koche R, Solary E, Sinha A, Preudhomme C, Abdel-Wahab O. ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nat Commun. 2017 May 18;8:15429. doi: 10.1038/ncomms15429. PubMed
- Lee SC, Abdel-Wahab O. Therapeutic targeting of splicing in cancer. Nat Med. 2016 Sep 7;22(9):976-86. doi: 10.1038/nm.4165. Review. PubMed
Selected Achievements
- Seldin-Smith Award for Pioneering Research, American Society of Clinical Investigation
- Pershing Square Sohn Prize for Young Investigators in Cancer Research
- Leukemia & Lymphoma Society Clinical Scholar Award
- Joanne Levy Memorial Award for Outstanding Achievement, American Society of Hematology
- V Scholar Award, V Foundation
